Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations
©2023 The Authors; Published by the American Association for Cancer Research..
PIK3CA mutations occur in ∼8% of cancers, including ∼40% of HR-positive breast cancers, where the PI3K-alpha (PI3Kα)-selective inhibitor alpelisib is FDA approved in combination with fulvestrant. Although prior studies have identified resistance mechanisms, such as PTEN loss, clinically acquired resistance to PI3Kα inhibitors remains poorly understood. Through serial liquid biopsies and rapid autopsies in 39 patients with advanced breast cancer developing acquired resistance to PI3Kα inhibitors, we observe that 50% of patients acquire genomic alterations within the PI3K pathway, including PTEN loss and activating AKT1 mutations. Notably, although secondary PIK3CA mutations were previously reported to increase sensitivity to PI3Kα inhibitors, we identified emergent secondary resistance mutations in PIK3CA that alter the inhibitor binding pocket. Some mutations had differential effects on PI3Kα-selective versus pan-PI3K inhibitors, but resistance induced by all mutations could be overcome by the novel allosteric pan-mutant-selective PI3Kα-inhibitor RLY-2608. Together, these findings provide insights to guide strategies to overcome resistance in PIK3CA-mutated cancers.
SIGNIFICANCE: In one of the largest patient cohorts analyzed to date, this study defines the clinical landscape of acquired resistance to PI3Kα inhibitors. Genomic alterations within the PI3K pathway represent a major mode of resistance and identify a novel class of secondary PIK3CA resistance mutations that can be overcome by an allosteric PI3Kα inhibitor. See related commentary by Gong and Vanhaesebroeck, p. 204 . See related article by Varkaris et al., p. 240 . This article is featured in Selected Articles from This Issue, p. 201.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Cancer discovery - 14(2024), 2 vom: 08. Feb., Seite 227-239 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Varkaris, Andreas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
22X328QOC4 |
|---|
| Anmerkungen: |
Date Completed 09.02.2024 Date Revised 11.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1158/2159-8290.CD-23-0704 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364088397 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364088397 | ||
| 003 | DE-627 | ||
| 005 | 20240211231929.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/2159-8290.CD-23-0704 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1288.xml |
| 035 | |a (DE-627)NLM364088397 | ||
| 035 | |a (NLM)37916958 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Varkaris, Andreas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.02.2024 | ||
| 500 | |a Date Revised 11.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2023 The Authors; Published by the American Association for Cancer Research. | ||
| 520 | |a PIK3CA mutations occur in ∼8% of cancers, including ∼40% of HR-positive breast cancers, where the PI3K-alpha (PI3Kα)-selective inhibitor alpelisib is FDA approved in combination with fulvestrant. Although prior studies have identified resistance mechanisms, such as PTEN loss, clinically acquired resistance to PI3Kα inhibitors remains poorly understood. Through serial liquid biopsies and rapid autopsies in 39 patients with advanced breast cancer developing acquired resistance to PI3Kα inhibitors, we observe that 50% of patients acquire genomic alterations within the PI3K pathway, including PTEN loss and activating AKT1 mutations. Notably, although secondary PIK3CA mutations were previously reported to increase sensitivity to PI3Kα inhibitors, we identified emergent secondary resistance mutations in PIK3CA that alter the inhibitor binding pocket. Some mutations had differential effects on PI3Kα-selective versus pan-PI3K inhibitors, but resistance induced by all mutations could be overcome by the novel allosteric pan-mutant-selective PI3Kα-inhibitor RLY-2608. Together, these findings provide insights to guide strategies to overcome resistance in PIK3CA-mutated cancers | ||
| 520 | |a SIGNIFICANCE: In one of the largest patient cohorts analyzed to date, this study defines the clinical landscape of acquired resistance to PI3Kα inhibitors. Genomic alterations within the PI3K pathway represent a major mode of resistance and identify a novel class of secondary PIK3CA resistance mutations that can be overcome by an allosteric PI3Kα inhibitor. See related commentary by Gong and Vanhaesebroeck, p. 204 . See related article by Varkaris et al., p. 240 . This article is featured in Selected Articles from This Issue, p. 201 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Phosphatidylinositol 3-Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.1.- |2 NLM | |
| 650 | 7 | |a Fulvestrant |2 NLM | |
| 650 | 7 | |a 22X328QOC4 |2 NLM | |
| 650 | 7 | |a Phosphoinositide-3 Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Class I Phosphatidylinositol 3-Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.1.137 |2 NLM | |
| 650 | 7 | |a PIK3CA protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.1.137 |2 NLM | |
| 700 | 1 | |a Fece de la Cruz, Ferran |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Elizabeth E |e verfasserin |4 aut | |
| 700 | 1 | |a Norden, Bryanna L |e verfasserin |4 aut | |
| 700 | 1 | |a Chevalier, Nicholas |e verfasserin |4 aut | |
| 700 | 1 | |a Kehlmann, Allison M |e verfasserin |4 aut | |
| 700 | 1 | |a Leshchiner, Ignaty |e verfasserin |4 aut | |
| 700 | 1 | |a Barnes, Haley |e verfasserin |4 aut | |
| 700 | 1 | |a Ehnstrom, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Stavridi, Anastasia-Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Janice S |e verfasserin |4 aut | |
| 700 | 1 | |a Ellis, Haley |e verfasserin |4 aut | |
| 700 | 1 | |a Papatheodoridi, Alkistis |e verfasserin |4 aut | |
| 700 | 1 | |a Gunaydin, Hakan |e verfasserin |4 aut | |
| 700 | 1 | |a Danysh, Brian P |e verfasserin |4 aut | |
| 700 | 1 | |a Parida, Laxmi |e verfasserin |4 aut | |
| 700 | 1 | |a Sanidas, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Yongli |e verfasserin |4 aut | |
| 700 | 1 | |a Lau, Kayao |e verfasserin |4 aut | |
| 700 | 1 | |a Wulf, Gerburg M |e verfasserin |4 aut | |
| 700 | 1 | |a Bardia, Aditya |e verfasserin |4 aut | |
| 700 | 1 | |a Spring, Laura M |e verfasserin |4 aut | |
| 700 | 1 | |a Isakoff, Steven J |e verfasserin |4 aut | |
| 700 | 1 | |a Lennerz, Jochen K |e verfasserin |4 aut | |
| 700 | 1 | |a Del Vecchio, Kathryn |e verfasserin |4 aut | |
| 700 | 1 | |a Pierce, Levi |e verfasserin |4 aut | |
| 700 | 1 | |a Pazolli, Ermira |e verfasserin |4 aut | |
| 700 | 1 | |a Getz, Gad |e verfasserin |4 aut | |
| 700 | 1 | |a Corcoran, Ryan B |e verfasserin |4 aut | |
| 700 | 1 | |a Juric, Dejan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer discovery |d 2011 |g 14(2024), 2 vom: 08. Feb., Seite 227-239 |w (DE-627)NLM215937023 |x 2159-8290 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:2 |g day:08 |g month:02 |g pages:227-239 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/2159-8290.CD-23-0704 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 2 |b 08 |c 02 |h 227-239 | ||